Not available
Quote | Natera Inc. (NASDAQ:NTRA)
Last: | $91.28 |
---|---|
Change Percent: | 2.13% |
Open: | $89.55 |
Close: | $91.28 |
High: | $91.365 |
Low: | $87.2 |
Volume: | 840,721 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Natera Inc. (NASDAQ:NTRA)
2024-04-24 09:30:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. The portfolio solidly outperformed the MSCI AC World Index. Holdings in health ca...
2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...
Message Board Posts | Natera Inc. (NASDAQ:NTRA)
Subject | By | Source | When |
---|---|---|---|
znewcar1: NTRA 21% v2,9M c43.51 f78,6M HH43.81 gap up dipped below VWAP S@40.2 | znewcar1 | investorshangout | 05/08/2020 12:29:43 AM |
News, Short Squeeze, Breakout and More Instantly...
Demonstrates commitment to generating real-world clinical evidence to change disease management and improve patient outcomes Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the...
ProActive study shows Natera’s Prospera Kidney™ test detects rejection five months before biopsy Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting ...
Prospective, multi-center Trifecta-Heart and DTRT-2 studies demonstrate excellent performance of the Prospera Heart test for detecting rejection in adults and pediatrics Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of...